Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Myriad's myChoice To Be Used In More Cancer Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .

You may also be interested in...



August M&A Analysis: Slow Month Highlighted By Unique Technologies

The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.

Myriad To Enter Neuroscience Market With $225m Assurex Acquisition

In its bid to develop more targeted diagnostics and build future partnerships with pharma companies, Myriad has signed a $225m deal, plus milestones, to acquire Assurex Health.

More Companion Diagnostic Deals For Qiagen And Myriad

Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel